Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy.
Follow him on Twitter @RealPatCampbell or reach him via email at [email protected].
Using real-world data from the US, Japan, and Sweden provides insight into contemporary trends in GDMT use, including initiation, uptitration, and discontinuation, following hospitalization among patients with heart failure with reduced ejection fraction.
Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.
Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.
To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.
As physician demands continue to climb in the high-demand specialty, patient-reported outcomes have emerged as a viable tool in assessment and care.
An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.
Reflections on a century's worth of developments toward a major breakthrough in T1D this year.
On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.
A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.
Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.
Viet Le, PA-C, discusses the results of a study examining characteristics and outcomes among pregnant statin users from EHR data recorded at Intermountain Healthcare medical centers.
Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.
A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.
Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.
Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.
An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.
Published on October 13, the latest scientific statement from the American Heart Association highlights the current role of patient-reported outcome measures in the management of peripheral artery disease as well as future considerations for optimizing this role and benefits in care.
The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.
An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.
A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.
Statins and their specific role have been the subject of debate for years. In this feature, 6 leading experts in cardiometabolic health share their perspectives on whether statins should be used in the sense of primordial prevention for ASCVD.
On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.
Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.
Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.
An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.
A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.
Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.
AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.
A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.
Data from a pivotal trial presented at ATTD 2022 demonstrate the use of the iLet Bionic Pancreas was associated with significant improvements in HbA1c and TIR among a diverse study population of adults and children with type 1 diabetes compared with standard care.
